Onorach Unveils China Plans
Onorach today announced plans to build a Clinical Trial Unit in China.
Stage 1 of the plans will be for a thirty-bed unit (incorporating both four bedded rooms and other individual rooms to comply with requirements of certain studies) with pharmacy, laboratory and other on-site ancillary services. Each ward will be independently temperature controlled and there will be a kitchen with dietician support to enable the CTU to conduct specific food studies. There is potential to expand the unit to 100 beds in the near future.
Managing Director / President Professor Christene Leiper said, “This is an exciting new step in the development of Onorach Clinical Trial Services. We will design, develop, and manage this CTU on an on-going basis with all staff trained to our international Good Clinical Practice - GCP standards. China provides great potential for Clinical Trial Studies with its very large population. China has significant chronic disease conditions that are amenable to new therapies, in particular Diabetes, Liver Disease, Obesity, and diseases associated with ageing".
Professor Leiper added "Our China site will be an ideal location for foreign companies to conduct clinical trials on Chinese subjects and for Chinese companies to conduct clinical trials to EMA and FDA standards within China - particularly in Generics and Traditional Chinese Medicines.”
Onorach will be able to facilitate clinical trials across all stages of drug development as well as Medical Devices, Biologicals and Vaccines.
For further information please contact: firstname.lastname@example.org